Details of the Drug Formulations

General Information of Drug (ID: DMHPRWG)

Drug Name
Exjade Drug Info
Synonyms Deferasirox
Indication
Disease Entry ICD 11 Status REF
Iron overload disease 5C64.10 Approved [1]
Cross-matching ID
PubChem CID
214348
ChEBI ID
CHEBI:49005
CAS Number
201530-41-8
TTD ID
D0Q5UQ
VARIDT ID
DR00452
ACDINA ID
D00172

Full List of Drug Formulations Containing This Drug

Deferasirox 125 mg tablet
Company Formulation ID FDA Description
Novartis Pharmaceuticals Corporation F05277 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Crospovidone; Povidone k30; Silicon dioxide; Cellulose, microcrystalline
------------------------------------------------------------------------------------
Deferasirox 180 mg tablet
Company Formulation ID FDA Description
Novartis Pharmaceuticals Corporation F05278 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Crospovidone; Povidone k30; Silicon dioxide; Cellulose, microcrystalline
------------------------------------------------------------------------------------
Deferasirox 250 mg tablet
Company Formulation ID FDA Description
Novartis Pharmaceuticals Corporation F05279 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Crospovidone; Povidone k30; Silicon dioxide; Cellulose, microcrystalline
------------------------------------------------------------------------------------
Deferasirox 360 mg tablet
Company Formulation ID FDA Description
Novartis Pharmaceuticals Corporation F05280 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Crospovidone; Povidone k30; Silicon dioxide; Cellulose, microcrystalline
------------------------------------------------------------------------------------
Deferasirox 500 mg tablet
Company Formulation ID FDA Description
Novartis Pharmaceuticals Corporation F05281 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Crospovidone; Povidone k30; Silicon dioxide; Cellulose, microcrystalline
------------------------------------------------------------------------------------
Deferasirox 90 mg tablet
Company Formulation ID FDA Description
Novartis Pharmaceuticals Corporation F05282 Magnesium stearate; Crospovidone; Poloxamer 188; Povidone k30; Silicon dioxide; Cellulose, microcrystalline
------------------------------------------------------------------------------------

References

1 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).